1. Search Result
Search Result
Results for "

nonhormonal

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14281
    Trilostane
    2 Publications Verification

    Win 24540

    3β-HSD Endocrinology Cancer
    Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer .
    Trilostane
  • HY-123035

    HSP Akt EGFR Endocrinology
    Gamendazole, an indazole carboxylic acid (ICA), is an orally active, selective HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A) inhibitor. Gamendazole binds to the C-terminal nucleotide binding pocket of HSP90 and cause downregulation of clients AKT1 and ERBB2, but stabilizes the HSP90 heterocomplex. Gamendazole specifically inhibits the actin bundling function of EEF1A1, but does not bind to the nucleotide docking pocket nor inhibits the ribosome charging or protein translation functions of EEF1A1. Gamendazole, an antispermatogenic compound with antifertility effects, has the potential for reversible non-hormonal male contraceptive agent research .
    Gamendazole
  • HY-14281R

    Win 24540 (Standard)

    Reference Standards Others Endocrinology Cancer
    Trilostane (Standard) is the analytical standard of Trilostane. This product is intended for research and analytical applications. Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer .
    Trilostane (Standard)
  • HY-14281S

    Win 24540-d3

    Isotope-Labeled Compounds Others
    Trilostane-d3 is the deuterium-labeled Trilostane (HY-14281). Trilostane-d3 (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane-d3 is a synthetic nonhormonal steroid. Trilostane-d3 can be used for the research of breast cancer and prostate cancer .
    Trilostane-d3
  • HY-129638

    Prostaglandin Receptor Endocrinology
    L-10503 is a non-hormonal non-prostaglandin antifertility compound .
    L-10503
  • HY-122349

    L-12717

    Drug Derivative Others
    Lotrifen is a non-hormonal compound with abortifacient effects. Lotrifen is most effective when used on the 20th day of pregnancy in beagle and mongrel dogs .
    Lotrifen
  • HY-177140

    Epigenetic Reader Domain Others
    CDD-1147 is a BRDT-BD2 inhibitor with an IC50 of 94 nM. CDD-1147 can be used in the research of non-hormonal contraceptives for men .
    CDD-1147
  • HY-139741

    DNA/RNA Synthesis Others
    cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) provides an avenue for developing a nonhormonal male contraceptive by blocking of GRTH/DDX25 phosphorylation.
    cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)
  • HY-177144

    Epigenetic Reader Domain Endocrinology
    CDD-1128 (Compound 11) is a potent inhibitor of BRDT-BD2. CDD-1128 has an IC50 of 521 nM against BRDT-BD2. CDD-1128 can be studied in research on nonhormonal contraceptive agent .
    CDD-1128
  • HY-177143

    Epigenetic Reader Domain Endocrinology
    CDD-1498 (Compound 12) is a potent inhibitor of BRDT-BD2. CDD-1498 has an IC50 of 978 nM against BRDT-BD2. CDD-1498 can be studied in research on nonhormonal contraceptive agent .
    CDD-1498
  • HY-177145

    Epigenetic Reader Domain Endocrinology
    CDD-1132 (Compound 8) is a potent inhibitor of BRDT-BD2. CDD-1132 has an IC50 of 13 nM against BRDT-BD2. CDD-1132 can be studied in research on nonhormonal contraceptive agent .
    CDD-1132
  • HY-177139

    Epigenetic Reader Domain Endocrinology
    CDD-1349 (Compound 15) is a BRDT-BD2/BRD4-BD2 selective inhibitor. CDD-1349is an analog with sixfold selectivity for BRDT-BD2 versus BRD4-BD2. CDD-1349 has an IC50 of 22 nM against BRDT. CDD-1349 can be studied in research on nonhormonal contraceptive agent .
    CDD-1349
  • HY-171129

    Ser/Thr Protease Endocrinology
    EP055 is a non-hormonal male contraceptive. EP055 targets to sperm protein EPPIN and inhibits anti-EPPIN antibodies from binding EPPIN with an IC50 of 1121 μM. EP055 can inhibit sperm motility (IC50 = 199.5 μM) by reducing the internal pH and Ca 2+ levels of the sperm, thereby causing the sperm to aggregate. EP055 can be used for development of male contraceptive .
    EP055
  • HY-182447

    DL111-IT

    CDK Apoptosis Endocrinology Cancer
    Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals .
    Contragestazol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: